Published guidance, policy, official data, or peer-reviewed evidence carries the claim.
Evidence brief
Evidence brief
Smarter Eczema Prescribing is built around evidence hygiene. Patient testimony can show what the system feels like when it fails. Published sources must carry clinical and policy claims. Promising but unresolved research threads stay marked Citation required.
Lived experience shows how pathways can break down, but it is not treated as clinical proof.
Important claims remain clearly marked until the source trail is verified.
Summary
The campaign separates argument, testimony, and proof.
Patient testimony can show where systems break down in practice. It cannot, by itself, prove population-level prevalence, clinical effectiveness, or total NHS cost.
The campaign's economic argument is that unit prescribing cost should be assessed alongside downstream care needs. Where the exact cost impact is not yet evidenced, the claim should remain marked as a research question or citation gap.
Already sourced
What the current source trail can support.
The existing sources support careful principles around emollient choice, acceptability, and policy context.
Choice and acceptability in emollient use
The campaign uses NICE and patient-facing eczema guidance for the sourced principle that choice, acceptability, and practical use matter in emollient care.
Quality standard for emollient provision, choice, and eczema care.
Clinical judgement in prescribing restrictions
NHS policy context is used to frame cost-conscious prescribing alongside clinical judgement, not as a reason to ignore documented need.
Policy context for routine prescribing restrictions and clinical judgement.
Patient testimony
What lived experience can show.
Testimony is useful for identifying recurring pathway failures and policy questions.
Patient testimony
A pathway signal, not clinical proof
Patient testimony helps show where prescribing pathways break down in practice. It should not replace clinical evidence, but repeated and consistent accounts can highlight problems that policy should investigate.
I could receive prescribed products at no personal cost, but the products available to me did not control my symptoms.
Patient testimony can show where systems break down in practice. It cannot, by itself, prove population-level prevalence, clinical effectiveness, or total NHS cost.
Citation required
What still needs citations.
The campaign leaves these claims visible as evidence gaps rather than publishing them as established fact.
- Citation required Current NHS dermatology waiting-time data.
- Citation required Cost evidence for repeat eczema appointments, flare management, infection, escalation, and referrals.
- Citation required Examples of formulary variation and documented exception routes.
- Citation required Patient evidence methodology and consent-led submission governance.
- Citation required Adjacent evidence questions, including probiotics or product-specific mechanisms, remain outside the launch argument unless independently verified from reliable primary sources.
- Citation required Any product-specific, ingredient-specific, probiotic strain, or mechanism claim.
Evidence gathering
Formal requests are being used to test the policy questions.
FOI responses are not treated as findings before they arrive.
Freedom of Information requests
Requests have been submitted to test what public bodies hold about formulary decisions, prescribing data, dermatology waits, non-formulary access, and adverse-event reporting.
View FOI requestsBoundaries
What the campaign will not claim.
These boundaries protect patients, clinicians, and the credibility of the policy ask.
- It will not recommend a product, ingredient, probiotic, or routine to patients.
- It will not present patient letters or testimony as clinical proof.
- It will not claim expensive products are automatically better.
- It will not publish strain identity, mechanism, or effectiveness claims until primary sources have been checked.
Next step
The evidence trail is part of the campaign, not an appendix.
Sources and gaps stay visible so policy readers can scrutinise the argument and help improve it.